ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	282.86	150.39	163.37	37.28
Cash & Short-Term Investments	282.86	150.39	163.37	37.28
Cash Growth	70.03%	-7.95%	338.23%	-
Other Receivables	0.5	0.76	0.5	0.25
Receivables	0.5	0.76	0.5	0.25
Prepaid Expenses	1.14	0.37	0.33	0.03
Other Current Assets	7.9	8.45	18.42	5.39
Total Current Assets	292.4	159.97	182.62	42.95
Property, Plant & Equipment	0.19	0.29	0.14	-
Long-Term Deferred Charges	-	2.73	-	-
Other Long-Term Assets	0.13	0.11	0.07	0.09
Total Assets	292.71	163.1	182.83	43.04
Accounts Payable	4.65	4.53	3.09	0.29
Accrued Expenses	10.36	6.95	5.14	1.53
Current Portion of Leases	0.16	0.14	0.13	-
Total Current Liabilities	15.16	11.62	8.36	1.82
Long-Term Leases	0.06	0.18	0.01	-
Total Liabilities	15.22	11.8	8.37	1.82
Additional Paid-In Capital	495.19	4.65	3.4	2.96
Retained Earnings	-217.7	-157.85	-88.51	-51.61
Comprehensive Income & Other	-	-	-	-0
Total Common Equity	277.49	-153.19	-85.11	-48.64
Shareholders' Equity	277.49	151.3	174.46	41.22
Total Liabilities & Equity	292.71	163.1	182.83	43.04
Total Debt	0.21	0.32	0.14	-
Net Cash (Debt)	282.64	150.07	163.23	37.28
Net Cash Growth	69.94%	-8.06%	337.86%	-
Net Cash Per Share	11.92	70.10	127.82	52.42
Filing Date Shares Outstanding	33.7	33.49	31.96	0.71
Total Common Shares Outstanding	33.69	2.75	2.6	0.71
Working Capital	277.24	148.34	174.26	41.13
Book Value Per Share	8.24	-55.80	-32.76	-68.40
Tangible Book Value	277.49	-153.19	-85.11	-48.64
Tangible Book Value Per Share	8.24	-55.80	-32.76	-68.40

Source: S&P Capital IQ. Standard template. Financial Sources.